Skip to main content

Table 1 Demographic, clinical and virological characteristics

From: Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay

Characteristic St. George’s (n = 59) NHS Lothian (n = 50)
Median age (IQR)a 44 (35–51) 42 (27–47)
No. males (%)b 28 (47) 34 (68)
Risk factor (#) heterosexualc 5 1
MSM 4 12
IVDU 0 1
MTCT 0 3
Not determined 50 33
Median HIV-1 RNA (IQR), log10 c/mld 4.62 (3.81–5.15) 4.76 (4.36–5.19)
Median CD4+ T cells (IQR), cell/mm3e 340 (157–490) 290 (106–485)
cART history—no. patients (%) Naivef 14 (24) 28 (56)
Experienced 45 (76) 22 (44)
cART regimen—no. patients (mean, range number of drugs) PIg 35 (2.3, 0–5) 17 (2.3, 0–5)
NRTI 45 (2.9, 1–7) 22 (3.6, 2–6)
NNRTI 24 (0.4, 0–1) 12 (0.8, 0–2)
INSTI 17 (0.4, 0–1) 6 (0.3, 0–1)
EI 4 (0.09, 0–1) None
  1. PI, protease inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; INSTI, integrase strand transfer inhibitors; entry inhibitors
  2. aMedian age at the time of sampling; IQR, interquartile range
  3. bNumber of male patients
  4. cMost likely mode of HIV-1 transmission: heterosexual; MSM, men who have sex with men; IVDU, intravenous drug user; MTCT, mother-to-child transmission; n.d., not determined
  5. dMedian HIV-1 RNA plasma load (log10 copies/ml) and IQR at the time the blood sample was obtained
  6. eMedian CD4+ T-cell count (cells/mm3) and IQR at the time the blood sample was obtained
  7. fNumber of patients treated (experienced) or not (naïve) with combination antiretroviral therapy (cART) at the time the blood sample was obtained
  8. gNumber of patients treated with cART, and mean number of antiretroviral drugs used per patient